key: cord-0911601-p595k9xe
authors: Chinitz, Larry A.
title: Atrial Arrhythmias and the Pandemic
date: 2021-09-20
journal: JACC Clin Electrophysiol
DOI: 10.1016/j.jacep.2021.03.011
sha: 324be9d91c10c6227141957efd28606837d48790
doc_id: 911601
cord_uid: p595k9xe

nan

Atrial Arrhythmias and the Pandemic* Exactly 1 year later, after more than 2.6 million deaths worldwide, we examine what we have learned and reassess the effect of the pandemic on our practice of medicine. The rapid, ubiquitous spread of this pathogen will probably be the greatest threat that societies will face in the 21st century, wreaking enormous turmoil on every aspect of our lives. Health care providers have been on the frontlines of the COVID-19 pandemic, often redeployed out of our comfort zones and asked to care for extraordinarily sick patients and illnesses remote from our primary area of expertise. As we witnessed the surging mortality, the harnessing of the clinical and basic research community to work together and identify best practices has been extraordinary and clearly made a profound impact on survival. We have had to adapt personally and professionally, and at present, even though the circumstances appear to be improving, it still feels that returning to our previous lives may never be possible. This may be particularly true for the practice of medicine, which will need to incorporate COVID-19, mutations, vaccinations, and personal protective equipment into daily planning. In the urgency to publish information related to COVID-19, many studies have used "big data," automated abstraction techniques to obtain information from electronic medical records (7) . Traditional analytics tools are not adapted to process such large amounts of unstructured data to pursue outcomes research. New tools that combine machine learning models for data analysis are being developed and will certainly be helpful (8) . At present, these automated There are many publications analyzing the prothrombotic state that appears to be present in patients with COVID-19 (9) . Hospitalized patients with COVID-19 have been observed to have a 16% incidence of any thrombotic event, of which 1.6% presented with an ischemic stroke. D-dimer level at presentation was independently associated with thrombotic events consistent with an early coagulopathy (10) . Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days (10) .

Given the established association of increased risk of 

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of Covid-19 in New York City

Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes and comparison to influenza

Inflammation, inflammasome activation, and atrial fibrillation

atrial fibrillation in covid-19: a review of possible mechanisms

Review of big data analytics, artificial intelligence and nature-inspired computing models towards accurate detection of COVID-19 pandemic cases and contact tracing

Thrombosis and coagulopathy in COVID-19

Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults $ 50 years with COVID-19

Thrombosis in hospitalized patients with COVID-19 in a New York City health system

Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology

KEY WORDS atrial fibrillation, COVID-19, inflammation

Atrial Fibrillation in Patients With COVID-19